{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:05:19Z","timestamp":1773975919492,"version":"3.50.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["FK 134343, K 146131"],"award-info":[{"award-number":["FK 134343, K 146131"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015763","name":"Szegedi Tudom\u00e1nyegyetem","doi-asserted-by":"publisher","award":["OA 8399"],"award-info":[{"award-number":["OA 8399"]}],"id":[{"id":"10.13039\/501100015763","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Fungal diseases represent a growing yet under-recognized global health threat, with mortality comparable to major infectious diseases but a disproportionately weak therapeutic pipeline. This review examines the antifungal innovation gap as a systemic phenomenon shaped by intertwined scientific, economic, and societal constraints. While multidrug-resistant pathogens underscore the urgent need for new antifungal agents, progress is hindered by fungal\u2013human cellular similarity, high development costs, limited commercial incentives, and toxicity concerns. Agricultural fungicide practices that drive resistance and intellectual-property regimes that restrict affordability and generic entry further complicate this landscape. These scientific and economic barriers coexist with profound inequities in global access to existing antifungals, revealing a persistent gap between therapeutic availability and public health needs. The resulting public-health consequences include delayed treatment, reliance on suboptimal therapies, and widening disparities in outcomes across low-resource settings. This review proposes that antifungal agents should be conceptualized as global public goods and that non-profit development models offer a promising pathway to overcome current bottlenecks. An integrated perspective across clinical, agricultural, regulatory, and public-health domains underscores the need for coordinated strategies to restore innovation, ensure equitable access, and strengthen global preparedness against fungal diseases.<\/jats:p>","DOI":"10.3389\/fcimb.2026.1797104","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T07:27:46Z","timestamp":1772090866000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Structural barriers to antifungal drug development"],"prefix":"10.3389","volume":"16","author":[{"given":"L\u00e1szl\u00f3","family":"Galg\u00f3czy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3201\/eid3101.240923","article-title":"Spread of antifungal-resistant Trichophyton indotineae, United Kingdom 2017\u20132024","volume":"31","author":"Abdolrasouli","year":"2024","journal-title":"Emerg. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.4103\/jfmpc.jfmpc_1582_24","article-title":"Invasive fungal infections and the management in immunocompromised conditions","volume":"14","author":"Anandani","year":"2025","journal-title":"J. Family Med. Prim. Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41579-019-0293-3","article-title":"Antibiotic development: economic, regulatory, and societal challenges","volume":"18","author":"\u00c5rdal","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"100902","DOI":"10.1016\/S2666-5247(24)00134-4","article-title":"WHO global research priorities for antimicrobial resistance in human health","volume":"5","author":"Bertagnolio","year":"2024","journal-title":"Lancet Microbe"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases\u2014estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J. Fungi"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/idr17040091","article-title":"Antifungal agents in the 21st century: advances, challenges, and future perspectives","volume":"17","author":"Branda","year":"2025","journal-title":"Infect. Dis. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2471\/BLT.18.229179","article-title":"Patent pooling to increase access to essential medicines","volume":"97","author":"Burrone","year":"2019","journal-title":"Bull. World Health Organ."},{"key":"B8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2217\/fmb.14.32","article-title":"Antifungal drug discovery: the process and outcomes","volume":"9","author":"Calderone","year":"2014","journal-title":"Future Microbiol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jof11040252","article-title":"Aspergillus fumigatus in the food production chain and azole resistance: a growing concern for consumers","volume":"11","author":"Castro-R\u00edos","year":"2025","journal-title":"J. Fungi"},{"key":"B10","volume-title":"The impact of global health R&D: The high return of investing in R&D for neglected diseases","author":"Chapman","year":"2024"},{"key":"B11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13054-025-05544-y","article-title":"Candida auris infections in ICU patients: risk factors, outcomes, and antifungal resistance patterns","volume":"29","author":"Choudhury","year":"2025","journal-title":"Crit. Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1136\/thoraxjnl-2015-207305","article-title":"The ambitious \u201c95\u201395 by 2025\u201d roadmap for the diagnosis and management of fungal diseases","volume":"70","author":"Denning","year":"2015","journal-title":"Thorax"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.drudis.2022.04.021","article-title":"Repurposing and optimization of drugs for discovery of novel antifungals","volume":"27","author":"Donlin","year":"2022","journal-title":"Drug Discov. Today"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14175936","article-title":"A 30-year epidemiological study of opportunistic fungal infections in people living with HIV","volume":"14","author":"Douvali","year":"2025","journal-title":"J. Clin. Med."},{"key":"B16","volume-title":"Equity at the heart of medical innovation: Annual report 2023","year":"2024"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e9200","DOI":"10.2903\/j.efsa.2025.9200","article-title":"Impact of the use of azole fungicides, other than as human medicines, on the development of azole-resistant Aspergillus spp","volume":"23","year":"2025","journal-title":"EFSA J."},{"key":"B18","first-page":"753166","article-title":"Improving public access to medicines and promoting pharmaceutical innovation","year":"2023","journal-title":"Eur. Parliament. Res. Serv."},{"key":"B19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","article-title":"Tackling the emerging threat of antifungal resistance to human health","volume":"20","author":"Fisher","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e00449","DOI":"10.1128\/mBio.00449-20","article-title":"Threats posed by the fungal kingdom to humans, wildlife, and agriculture","volume":"11","author":"Fisher","year":"2020","journal-title":"mBio"},{"key":"B21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1021\/acsbiomedchemau.5c00103","article-title":"Overcoming global antifungal challenges: medical and agricultural aspects","volume":"5","author":"Galg\u00f3czy","year":"2025","journal-title":"ACS Bio Med. Chem. Au"},{"key":"B22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cmi.2024.08.006","article-title":"Invasive fungal disease in the immunocompromised host: changing epidemiology, new antifungal therapies, and management challenges","volume":"31","author":"Giannella","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1016\/S1473-3099(23)00455-3","article-title":"Overcoming publication and dissemination bias in infectious diseases clinical trials","volume":"24","author":"Grobusch","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e00458","DOI":"10.1128\/aac.00458-22","article-title":"Triazole priming as an adaptive response and gateway to resistance in Aspergillus fumigatus","volume":"66","author":"Harish","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41564-024-01720-y","article-title":"Pan-drug resistance and hypervirulence in a human fungal pathogen are enabled by mutagenesis induced by mammalian body temperature","volume":"9","author":"Huang","year":"2024","journal-title":"Nat. Microbiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40588-024-00219-8","article-title":"Emerging antifungal resistance in fungal pathogens","volume":"11","author":"Hui","year":"2024","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/jac\/dkw325","article-title":"Global access to antifungal therapy and its variable cost","volume":"71","author":"Kneale","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10071317","article-title":"Lomentospora prolificans: an emerging opportunistic fungal pathogen","volume":"10","author":"Konsoula","year":"2022","journal-title":"Microorganisms"},{"key":"B29","first-page":"1","article-title":"Fungal diseases: health burden, neglectedness, and research funding","volume":"1","author":"Lapp\u00e9","year":"2024","journal-title":"Rethink Priorities"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1662442","article-title":"New antifungal strategies and drug development against WHO critical priority fungal pathogens","volume":"15","author":"Li","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1016\/j.apsb.2025.06.013","article-title":"Next-generation antifungal drugs: mechanisms, efficacy, and clinical prospects","volume":"15","author":"Lu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","volume":"2","author":"Lundh","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B33","volume-title":"Greater access to medicines and health technologies for those who need them: Annual report 2022","year":"2023"},{"key":"B34","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.clinthera.2021.11.019","article-title":"Industry sponsor influence in clinical trial reporting in Canada: a qualitative interview study","volume":"44","author":"Morrow","year":"2022","journal-title":"Clin. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4236\/pp.2024.154007","article-title":"Global burden of fungal infections and antifungal resistance from 1961 to 2024: findings and future implications","volume":"15","author":"Mudenda","year":"2024","journal-title":"Pharmacol. Pharm."},{"key":"B36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/978-3-031-53793-6_22","article-title":"Funding for equitable infectious disease research and development","volume-title":"Transforming Global Health Partnerships","author":"Mwoka","year":"2024"},{"key":"B37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.drudis.2014.08.010","article-title":"Can agricultural fungicides accelerate the discovery of human antifungal drugs","volume":"20","author":"Myung","year":"2015","journal-title":"Drug Discov. Today"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/jof10120871","article-title":"New ground in antifungal discovery and therapy for invasive fungal infections: innovations, challenges, and future directions","volume":"10","author":"Ni\u00f1o-Vega","year":"2024","journal-title":"J. Fungi"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e0212723","DOI":"10.1128\/spectrum.02127-23","article-title":"Evolutionary trends in antifungal resistance: a meta-analysis","volume":"12","author":"Niu","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0014223","DOI":"10.1128\/cmr.00142-23","article-title":"Advancements and challenges in antifungal therapeutic development","volume":"37","author":"Puumala","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e0278964","DOI":"10.1371\/journal.pone.0278964","article-title":"Striving towards access to essential medicines for human and animal health: a situational analysis of access to and use of antifungal medications for histoplasmosis in Ethiopia","volume":"18","author":"Robertson","year":"2023","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0007964","DOI":"10.1371\/journal.pntd.0007964","article-title":"Fungal diseases as neglected pathogens: a wake-up call to public health officials","volume":"14","author":"Rodrigues","year":"2020","journal-title":"PloS Negl. Trop. Dis."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.00036","article-title":"Antifungal therapy: new advances in the understanding and treatment of mycosis","volume":"8","author":"Scorzoni","year":"2017","journal-title":"Front. Microbiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e2343425","DOI":"10.1001\/jamanetworkopen.2023.43425","article-title":"Industry involvement and transparency in the most cited clinical trials 2019\u20132022","volume":"6","author":"Siena","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/jof9080820","article-title":"Public health research priorities for fungal diseases: a multidisciplinary approach to save lives","volume":"9","author":"Smith","year":"2023","journal-title":"J. Fungi"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e31801","DOI":"10.1371\/journal.pone.0031801","article-title":"Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus","volume":"7","author":"Snelders","year":"2012","journal-title":"PloS One"},{"key":"B47","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12992-022-00826-4","article-title":"What is the impact of intellectual property rules on access to medicines? A systematic review","volume":"18","author":"Tenni","year":"2022","journal-title":"Global Health"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/jof8070757","article-title":"Trichophyton indotineae\u2014an emerging pathogen causing recalcitrant dermatophytoses in India and worldwide: a multidimensional perspective","volume":"8","author":"Uhrla\u00df","year":"2022","journal-title":"J. Fungi"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf382","article-title":"Antifungal treatment strategies and their impact on resistance development in clinical settings","author":"Van Rhijn","year":"2025","journal-title":"J. Antimicrob. Chemother"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s44259-023-00007-2","article-title":"Molecular mechanisms governing antifungal drug resistance","volume":"1","author":"Verma","year":"2023","journal-title":"NPJ Antimicrob. Resist."},{"key":"B51","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S1473-3099(09)70265-8","article-title":"Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use","volume":"9","author":"Verweij","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e1012219","DOI":"10.1371\/journal.ppat.1012219","article-title":"Effects of climate change on fungal infections","volume":"20","author":"Williams","year":"2024","journal-title":"PloS Pathog."},{"key":"B53","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.riam.2024.11.001","article-title":"Antifungal pipeline: new tools for the treatment of mycoses","volume":"41","author":"Wolfgruber","year":"2024","journal-title":"Rev. Iberoamericana Micolog\u00eda"},{"key":"B54","volume-title":"WHO fungal priority pathogens list to guide research, development and public health action","year":"2022"},{"key":"B55","volume-title":"Antifungal agents in clinical and preclinical development: overview and analysis","year":"2025"},{"key":"B56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12992-024-01035-x","article-title":"Characteristics and outcomes of the drug patent linkage system in China","volume":"20","author":"Yao","year":"2024","journal-title":"Global Health"},{"key":"B57","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/17435390.2024.2340467","article-title":"Advances in nanotechnology for improving the targeted delivery and activity of amphotericin B, (2011\u20132023): a systematic review","volume":"18","author":"Zadeh Mehrizi","year":"2024","journal-title":"Nanotoxicology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1694108","article-title":"The rising challenge of Candida auris: insights into its transmission, drug resistance, and infection control strategies","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Microbiol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1797104\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T07:27:48Z","timestamp":1772090868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1797104\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":58,"alternative-id":["10.3389\/fcimb.2026.1797104"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1797104","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"article-number":"1797104"}}